Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced the pricing of its underwritten public offering of 2,500,000 shares of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE